| Outcome Measures: |
Primary: Change in renal function from baseline after 2 year of treatment as assessed by EPI-estimated glomerular filtration rate (eGFR), 2 years | Secondary: Change in renal function from baseline after 1 year of treatment as assessed by EPI-estimated glomerular filtration rate (eGFR), 1 year|Change in urine protein from baseline after 1 and 2 years of treatment as assessed by urinary albumin-to-creatinine ratio(UACR), 1 and 2 years|50% decrease of albumin-to-creatinine ratio (UACR) from baseline after 1 and 2 years of treatment, 1 and 2 years|Incidence of kidney composite endpoint including end-stage renal disease (ESRD), kidney replacement therapy, or sustained EPI-estimated glomerular filtration rate (eGFR) decline ≥ 40%., 1 and 2 years|Incidence of sustained EPI-estimated glomerular filtration rate (eGFR) < 15 ml/min/1.73 m², 1 and 2 years|Incidence of cardiovascular endpoints including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or heart failure hospitalization, 1 and 2 years|Changes in cardiac injury after 1 and 2 years of treatment from baseline as assessed by left ventricular mass index or E/E' or cardiac troponin, 1 and 2 years|Changes in pulse wave velocity (PWV) after 1 and 2 years of treatment from baseline, 1 and 2 years|Incidence of mortality including all-cause, cardiovascular-related, and renal-related., 1 and 2 years|Changes in office and ambulatory blood pressure levels after 1 and 2 years of treatment from baseline, 1 and 2 years|Hypotension-related adverse events, dizziness, falls, office blood pressure below 90/60 mmHg, orthostatic hypotension (blood pressure drop exceeding 20/10 mmHg within 3 minutes of standing compared to sitting), and acute kidney injury \[serum creatinine increase ≥0.3 mg/dl (≥26.5 μmol/L) within 48 hours; or serum creatinine rising to ≥1.5 times baseline value within 7 days; or urine output \<0.5 mL/(kg·h) for ≥ 6 hours\]., 1 and 2 years
|
